Search Results - "Powderly, J.D."

Long-term Survival, Clinical Activity, and Safety of Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC) by Gettinger, S.N, Horn, L, Gandhi, L, Spigel, D.R, Antonia, S.J, Rizvi, N.A, Powderly, J.D, Heist, R.S, Carvajal, R.D, Jackman, D.M, Sequist, L.V, Smith, D.C, Leming, P.D, Topalian, S.L, Hodi, F, Sznol, M, Harbison, C.T, Kollia, G.D, Brahmer, J.R

Get full text

730MO First-in-human phase I study of INCAGN02390, a TIM-3 monoclonal antibody antagonist in patients with advanced malignancies by Gutierrez, M.E., Tang, S-C., Powderly, J.D., Balmanoukian, A.S., Janik, J., Hoyle, P., Wei, W., Gong, X., Hamid, O.

Get full text

464 (PB452): Determination of the phase 2 dose of AU-007, an AI-designed human monoclonal antibody that redirects IL-2 to T-effector cells by Wyant, T., McKean, M., Rasco, D., Haydon, A.M., Powderly, J.D., Weickhardt, A.J., Ahern, E.S., De Souza, P., Ganju, V., Hu-Lieskovan, S., Kichenadasse, G., Tang, J., Richards, L., Knickerbocker, A., Amit, I., Ofran, Y., Vasselli, J.

Get full text

742P First-in-human phase I study of INCAGN02385, a LAG-3 monoclonal antibody antagonist in patients with advanced malignancies by Powderly, J.D., Hamid, O., Gutierrez, M.E., Balmanoukian, A.S., Janik, J., Hoyle, P., Dong, Z., Wei, W., Chen, X., Bourayou, N., Horn, L.

Get full text

1185TiP First-in-human phase I study of ABBV-637 as monotherapy and in combination in patients with relapsed and refractory solid tumors by Rotow, J., Yoh, K., Powderly, J.D., Shimizu, T., Perets, R., Paz-Ares, L., Phillips, A., Souers, A., Ansell, P.J., Jin, J., Badawi, M., Saab, R., Morrison-Thiele, G., Jeffries, S., Neagu Aristide, M.R., Carneiro, B.A., Papadopoulos, K.P.

Get full text

780TiP A phase I dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of CLN-619 (anti-MICA/MICB Antibody) alone and in combination with pembrolizumab in patients with advanced malignancies by Hamilton, E.P., Melero, I., Lugowska, I., Arance Fernandez, A.M., Vila Martinez, L., Powderly, J.D., Gutierrez, M., Serino, T., Mehta, N., Shapiro, I., Whalen, K., Michaelson, J., Jones, J., Janik, J.E., Moreno Garcia, V.

Get full text

A Phase 2, Non-Comparative, Open-Label, International Study of MEDI4736 in Patients with Locally Advanced or Metastatic PD-L1-Positive NSCLC (Stage IIIB-IV) Who have Received ≥ 2 Prior Systemic Treatment Regimens (Atlantic) by Rizvi, N., Ballas, M., Jayawardene, D., Stockman, P.K., Powderly, J.D.

Get full text

Phase 2, Open-Label, International, Non-Comparative Study of MEDI4736 in Patients with Locally Advanced or Metastatic, Pd-L1 +, Stage 3B–4 Nsclc Who Have Received ≥2 Prior Systemic Treatment Regimens (ATLANTIC) by Gray, J.E., Garassino, M.C., Vansteenkiste, J.F., Ballas, M., Jayawardene, D., Stockman, P.K., Powderly, J.D., Rizvi, N.

Get full text

1335TiPA PHASE 2, NON-COMPARATIVE, OPEN-LABEL, MULTICENTER, INTERNATIONAL STUDY OF MEDI4736 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PD-L1-POSITIVE NSCLC (STAGE IIIB-IV) WHO HAVE RECEIVED ≥ 2 PRIOR SYSTEMIC TREATMENT REGIMENS, INCLUDING A PLATINUM-BASED CHEMOTHERAPY (ATLANTIC) by Rizvi, N., Gray, J., Ballas, M., Jayawardene, D., Stockman, P., Powderly, J.D.

“…Abstract Background: Programmed cell death-ligand 1 (PD-L1) is a cell surface protein that delivers inhibitory signals to T cells through interaction with the…”
Get full text

A Phase 2, Non-Comparative, Open-Label, Multicenter, International Study of Medi4736 in Patients with Locally Advanced or Metastatic Pd-L1-Positive Nsclc (Stage Iiib-Iv) Who Have Received ≥ 2 Prior Systemic Treatment Regimens, Including a Platinum-Based Chemotherapy (Atlantic) by Rizvi, N., Gray, J., Ballas, M., Jayawardene, D., Stockman, P., Powderly, J.D.

Get full text

1049OSAFETY AND EFFICACY OF MPDL3280A (ANTI-PDL1) IN COMBINATION WITH BEVACIZUMAB (BEV) AND/OR CHEMOTHERAPY (CHEMO) IN PATIENTS (PTS) WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS by Lieu, C., Bendell, J., Powderly, J.D., Pishvaian, M.J., Hochster, H., Eckhardt, S.G., Funke, R., Rossi, C., Waterkamp, D., Hurwitz, H.

“…Abstract Aim: PD-L1 mediates cancer immune evasion, and blocking PD-L1 represents a cancer immunotherapy strategy that can restore tumor-specific T-cell…”
Get full text

Safety and Efficacy of Mpdl3280A (Anti-Pdl1) in Combination with Bevacizumab (Bev) and/or Chemotherapy (Chemo) in Patients (Pts) with Locally Advanced or Metastatic Solid Tumors by Lieu, C., Bendell, J., Powderly, J.D., Pishvaian, M.J., Hochster, H., Eckhardt, S.G., Funke, R., Rossi, C., Waterkamp, D., Hurwitz, H.

Get full text

Long-term Survival, Clinical Activity, and Safety of Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC): Metastatic Non-Small Cell Lung Cancer by Gettinger, S.N., Horn, L., Gandhi, L., Spigel, D.R., Antonia, S.J., Rizvi, N.A., Powderly, J.D., Heist, R.S., Carvajal, R.D., Jackman, D.M., Sequist, L.V., Smith, D.C., Leming, P.D., Topalian, S.L., Hodi, F., Sznol, M., Harbison, C.T., Kollia, G.D., Brahmer, J.R.

Get full text

Clinical Activity and Safety of Anti-Programmed Death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in Patients (PTS) with Previously Treated, Metastatic Renal Cell Carcinoma (MRCC) by McDermott, D.F., Drake, C.G., Sznol, M., Choueiri, T.K., Powderly, J.D., Smith, D.C., Wigginton, J.M., Kollia, G., Gupta, A., Atkins, M.B.

Get full text

Long-Term Survival of Ipilimumab-Naïve Patients (Pts) with Advanced Melanoma (Mel) Treated with Nivolumab (Anti-Pd-1; Bms-936558, Ono-4538) in a Phase 1 Trial by McDermott, D.F., Kluger, H., Sznol, M., Carvajal, R., Lawrence, D., Topalian, S.L., Atkins, M.B., Powderly, J.D., Sharfman, W.H., Puzanov, I., Smith, D.C., Leming, P.D., Lipson, E., Taube, J.M., Anders, R.A., Horak, C., Kollia, G., Sosman, J.A., Hodi, F.S.

Get full text

1088PDLONG-TERM SURVIVAL OF IPILIMUMAB-NAïVE PATIENTS (PTS) WITH ADVANCED MELANOMA (MEL) TREATED WITH NIVOLUMAB (ANTI-PD-1; BMS-936558, ONO-4538) IN A PHASE 1 TRIAL by McDermott, D.F., Kluger, H., Sznol, M., Carvajal, R., Lawrence, D., Topalian, S.L., Atkins, M.B., Powderly, J.D., Sharfman, W.H., Puzanov, I., Smith, D.C., Leming, P.D., Lipson, E., Taube, J.M., Anders, R.A., Horak, C., Kollia, G., Sosman, J.A., Hodi, F.S.

“…Abstract Aim: Nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, is active and tolerable in pts with advanced MEL (Topalian et al. NEJM…”
Get full text